{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-23-000013","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.672532+00:00","generated_at":"2026-06-15T03:50:26.426626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start","bullets":["Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.","Phase 1 of GFH009 in AML completed; 94% of patients alive, durable remission >6 months; Phase 2a starting Q2.","Phase 3 REGAL study of GPS in AML on track for interim analysis late 2023/early 2024; IDMC OK.","3D Medicines to trigger $13M milestone payments by Q3 2023 via REGAL participation in China.","No licensing revenue in Q1 2023 (vs $1M in Q1 2022); R&D expenses rose to $7.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-23-000013","json":"https://secwatch.observer/filing/0001390478-23-000013.json","markdown":"https://secwatch.observer/filing/0001390478-23-000013.md","text":"https://secwatch.observer/filing/0001390478-23-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/0001390478-23-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/sls-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:50:26.426626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1dbbb874e8580a78990535e532d3e9748b376a0","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/0001390478-23-000013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}